4YX0 Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.23K
Market Cap
€9.51M
Enterprise Value-€1.10
Total Cash (Recent Filing)€9.05M
Total Debt (Recent Filing)€286.64K
Price to Earnings (P/E)―
Beta-1.28
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding614,124,760
10 Day Avg. Volume4,070
30 Day Avg. Volume2,226
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.87
Price to Sales (P/S)2.48
P/FCF Ratio-4.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Long-term Revenue BaseRevenue has grown from a very small 2021 base to about $4.2M in 2026, indicating established commercial demand for legal psilocybin products. This provides a foundation for scale if distribution and regulated-market access expand.
Low LeverageTotal debt of about $0.29M in 2026 leaves the company less exposed to interest costs and refinancing pressure than a heavily leveraged peer. This flexibility can support continuity while management works toward profitability.
Positive Gross ProfitGross profit was about $1.2M in 2026, and margins improved materially from extreme loss levels in 2021–2022. Positive product-level gross profit suggests the offering can cover direct costs, although overhead remains too high.
Bears Say
Uneven Revenue TrendRevenue fell in 2026 versus 2025, showing that the commercial trajectory is uneven despite longer-term growth. A declining top line can weaken operating leverage and make fixed compliance, production, and distribution costs harder to absorb.
Persistent Operating LossesEBIT was about -$4.4M and net loss about -$6.1M on $4.2M of 2026 revenue. Losses this large relative to sales show that overhead and operating costs remain structurally misaligned with the revenue base.
Negative Cash GenerationOperating cash flow is negative in every year shown and free cash flow reached about -$2.6M in 2026. Continued cash burn means the business has not demonstrated self-funding and may require additional financing to sustain operations.
Red Light Holland News
4YX0 FAQ
What was Red Light Holland’s price range in the past 12 months?
Red Light Holland lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Red Light Holland’s market cap?
Red Light Holland’s market cap is €9.51M.
When is Red Light Holland’s upcoming earnings report date?
Red Light Holland’s upcoming earnings report date is Dec 02, 2026 which is in 95 days.
How were Red Light Holland’s earnings last quarter?
Currently, no data Available
Is Red Light Holland overvalued?
According to Wall Street analysts Red Light Holland’s price is currently Overvalued.
Does Red Light Holland pay dividends?
Red Light Holland does not currently pay dividends.
What is Red Light Holland’s EPS estimate?
Red Light Holland’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Red Light Holland have?
Red Light Holland has 614,124,760 shares outstanding.
What happened to Red Light Holland’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Red Light Holland?
Currently, no hedge funds are holding shares in DE:4YX0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Red Light Holland
Based in Toronto, Ontario, Red Light Holland Corp. is primarily involved in the cultivation, production, and retail of recreational magic truffles for the Dutch market. Beyond its own cultivated offerings, the company also engages in the sourcing, distribution, and international export of various truffle varieties. Its diverse product portfolio further extends to include cannabidiol (CBD) products, cannabis seeds, headshop essentials, and a selection of cannabis-infused baked goods like muffins, cookies, and cakes. These items are marketed under the iMicrodose and Maka brands and are available to consumers through 74 brick-and-mortar SmartShops, the iMicrodose.nl website, and several other online retail platforms throughout the Netherlands.
Technical Analysis
Good Shroom Co Inc
―
Revive Therapeutics
―
Charlotte's Web Holdings
―
Curaleaf Holdings
―
Planet 13 Holdings
―